256 related articles for article (PubMed ID: 26474564)
1. How Long to Treat with Denosumab.
Costa AG; Bilezikian JP
Curr Osteoporos Rep; 2015 Dec; 13(6):415-20. PubMed ID: 26474564
[TBL] [Abstract][Full Text] [Related]
2. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
3. New anti-resorptives and antibody mediated anti-resorptive therapy.
Farrier AJ; Sanchez Franco LC; Shoaib A; Gulati V; Johnson N; Uzoigwe CE; Choudhury MZ
Bone Joint J; 2016 Feb; 98-B(2):160-5. PubMed ID: 26850419
[TBL] [Abstract][Full Text] [Related]
4. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the Jaw.
Hamdy RC
J Clin Densitom; 2017; 20(1):1-2. PubMed ID: 28259260
[No Abstract] [Full Text] [Related]
6. Hypocalcaemia after denosumab in older people following fracture.
Chen J; Smerdely P
Osteoporos Int; 2017 Feb; 28(2):517-522. PubMed ID: 27682248
[TBL] [Abstract][Full Text] [Related]
7. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
8. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL;
Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
[TBL] [Abstract][Full Text] [Related]
9. The inhibition of RANK-ligand in the management of postmenopausal osteoporosis and related fractures: the role of denosumab.
Capozzi A; Lello S; Pontecorvi A
Gynecol Endocrinol; 2014 Jun; 30(6):403-8. PubMed ID: 24592987
[TBL] [Abstract][Full Text] [Related]
10. Data from extension trials: denosumab and zoledronic acid.
Dore RK
Curr Osteoporos Rep; 2012 Mar; 10(1):16-21. PubMed ID: 22086442
[TBL] [Abstract][Full Text] [Related]
11. Cancel the denosumab holiday.
McClung MR
Osteoporos Int; 2016 May; 27(5):1677-82. PubMed ID: 26932443
[No Abstract] [Full Text] [Related]
12. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
[TBL] [Abstract][Full Text] [Related]
13. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
[TBL] [Abstract][Full Text] [Related]
14. Denosumab after 8 years.
Reid IR
Osteoporos Int; 2015 Dec; 26(12):2759-61. PubMed ID: 26475285
[No Abstract] [Full Text] [Related]
15. [Bisphosphonates (BP) and osteonecrosis of the jaws; continuous treatment with Bisphosphonates should be considered].
Mawatari T
Clin Calcium; 2010 Nov; 20(11):1743-7. PubMed ID: 21066910
[No Abstract] [Full Text] [Related]
16. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review.
Kendler DL; Cosman F; Stad RK; Ferrari S
Adv Ther; 2022 Jan; 39(1):58-74. PubMed ID: 34762286
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab.
Neuprez A; Coste S; Rompen E; Crielaard JM; Reginster JY
Osteoporos Int; 2014 Jan; 25(1):393-5. PubMed ID: 23835864
[TBL] [Abstract][Full Text] [Related]
18. Denosumab: a novel antiresorptive drug for osteoporosis.
Suresh E; Abrahamsen B
Cleve Clin J Med; 2015 Feb; 82(2):105-14. PubMed ID: 25897599
[TBL] [Abstract][Full Text] [Related]
19. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
Adler RA
Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
[TBL] [Abstract][Full Text] [Related]
20. Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment.
Ferrari S; Butler PW; Kendler DL; Miller PD; Roux C; Wang AT; Huang S; Wagman RB; Lewiecki EM
J Clin Endocrinol Metab; 2019 Aug; 104(8):3450-3461. PubMed ID: 31125092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]